DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Tay-Sachs disease AB variant — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTay-Sachs disease AB variant maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tay-sachs disease ab variant is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ganglioside GM2 activator (GM2A) — GM2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 7rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2AG4 · 1.8 Å · ligand (7R)-4,7-DIHYDROXY-N,N,N-TRIMETHYL-10-OXO-3,5,9-TRIOXA-4-PHOSPHAHEPTACOSAN-1-AMINIUM 4-OXIDE (LP3). Experimental structure, not a prediction.
What the evidence adds up to
Tay-Sachs disease is an autosomal recessive lysosomal storage disorder caused by mutations in the HEXA gene, which encodes the alpha subunit of beta-hexosaminidase A. The resulting enzyme deficiency leads to GM2 ganglioside accumulation in nerve cells, triggering neurodegeneration, microglia expansion, and neuroinflammation. A 1997 review catalogued 78 mutations in the HEXA gene, including 65 single base substitutions, one large deletion of 7.5 kilobases, 10 small deletions, and two small insertions. Among Ashkenazi Jewish carriers, a four-base insertion in exon 11 accounts for 80% of cases; a large deletion is the major mutation in French Canadian carriers. Most other mutations are confined to single pedigrees. Clinical severity depends on residual enzyme activity, with infantile, juvenile, and late-onset forms described.
A 2017 study from Tabriz, Iran, notes that the protein sequence of alpha and beta subunits has been determined from cDNA, clarifying the lysosomal processing pathway. A 2018 review states that current treatment is limited to symptom relief and, in late-onset cases, delay of progression. Clinical reports exist of substrate reduction therapy with miglustat and of bone marrow or haematopoietic stem cell transplantation. Gene therapy using adeno-associated virus vectors to deliver alpha and beta subunit cDNA is under evaluation in alpha or beta subunit defective mice and in Jacob sheep, which spontaneously develop Tay-Sachs with the same pathological features as humans. The review describes these approaches as at the development stage.
A 2022 study characterised nine new patients with Late-Onset Tay-Sachs (LOTS) and reviewed 76 additional patients from the literature. The presentation is multifaceted, with neuromuscular, cerebellar, psychiatric, stuttering, or movement disorder phenotypes. Diagnostic clues include the triceps sign, distinct speech patterns, early psychiatric presentation with impulsivity, and neurological symptoms in patients with prominent psychiatric features. The authors state that clinical trials are now becoming available for LOTS, making early diagnosis important for informative research outcomes. They provide the first video presentation of a LOTS cohort.
What is still missing is evidence from completed clinical trials showing that any intervention alters the course of the disease. The gene therapy approaches remain in animal models. The substrate reduction and transplantation reports are described as clinical reports, not controlled trials. For LOTS, the availability of trials is mentioned but no results are given. Patient stratification by mutation type and residual enzyme activity may be necessary, and funding for definitive human studies remains a barrier.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Physiology · 2018 · 119 citations · open access
New Approaches to Tay-Sachs Disease Therapy
AbstractTay-Sachs disease belongs to the group of autosomal-recessive lysosomal storage metabolic disorders. This disease is caused by β-hexosaminidase A (HexA) enzyme deficiency due to various mutations in α-subunit gene of this enzyme, resulting in GM2 ganglioside accumulation predominantly in lysosomes of nerve cells. Tay-Sachs disease is characterized by acute neurodegeneration preceded by activated microglia expansion, macrophage and astrocyte activation along with inflammatory mediator production. In most cases, the disease manifests itself during infancy, the "infantile form," which characterizes the most severe disorders of the nervous system. The juvenile form, the symptoms of which appear in adolescence, and the most rare form with late onset of symptoms in adulthood are also described. The typical features of Tay-Sachs disease are muscle weakness, ataxia, speech, and mental disorders. Clinical symptom severity depends on residual HexA enzymatic activity associated with some mutations. Currently, Tay-Sachs disease treatment is based on symptom relief and, in case of the late-onset form, on the delay of progression. There are also clinical reports of substrate reduction therapy using miglustat and bone marrow or hematopoietic stem cell transplantation. At the development stage there are methods of Tay-Sachs disease gene therapy using adeno- or adeno-associated viruses as vectors for the delivery of cDNA encoding α and β HexA subunit genes. Effectiveness of this approach is evaluated in α or β HexA subunit defective model mice or Jacob sheep, in which Tay-Sachs disease arises spontaneously and is characterized by the same pathological features as in humans. This review discusses the possibilities of new therapeutic strategies in Tay-Sachs disease therapy aimed at preventing neurodegeneration and neuroinflammation.
Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene
AbstractTay-Sachs disease is an autosomal recessive disorder affecting the central nervous system. The disorder results from mutations in the gene encoding the alpha-subunit of beta-hexosaminidase A, a lysosomal enzyme composed of alpha and beta polypeptides. Seventy-eight mutations in the Hex A gene have been described and include 65 single base substitutions, one large and 10 small deletions, and two small insertions. Because these mutations cripple the catalytic activity of beta-hexosaminidase to varying degrees, Tay-Sachs disease displays clinical heterogeneity. Forty-five of the single base substitutions cause missense mutations; 39 of these are disease causing, three are benign but cause a change in phenotype, and three are neutral polymorphisms. Six nonsense mutations and 14 splice site lesions result from single base substitutions, and all but one of the splice site lesions cause a severe form of Tay-Sachs disease. Eight frameshift mutations arise from six deletion- and two insertion-type lesions. One of these insertions, consisting of four bases within exon 11, is found in 80% of the carriers of Tay-Sachs disease from the Ashkenazi Jewish population, an ethnic group that has a 10-fold higher gene frequency for a severe form of the disorder than the general population. A very large deletion, 7.5 kilobases, including all of exon 1 and portions of DNA upstream and downstream from that exon, is the major mutation found in Tay-Sachs disease carriers from the French Canadian population, a geographic isolate displaying an elevated carrier frequency. Most of the other mutations are confined to single pedigrees. Identification of these mutations has permitted more accurate carrier information, prenatal diagnosis, and disease prognosis. In conjunction with a precise tertiary structure of the enzyme, these mutations could be used to gain insight into the structure-function relationships of the lysosomal enzyme.
Tremor and Other Hyperkinetic Movements · 2022 · 11 citations · open access
Diagnostic Tips from a Video Series and Literature Review of Patients with Late-Onset Tay-Sachs Disease
AbstractBackground: Late-Onset Tay-Sachs (LOTS) disease is a rare, progressive neurological condition that can dramatically affect the life of these patients. The diagnosis of LOTS is easily missed because of the multifaced presentation of these patients, who can initially be assessed by neuromuscular or movement disorder specialists, or psychiatrists. Clinical trials are now becoming available for LOTS. Therefore, early diagnosis can be detrimental for these patients and for insuring informative research outcomes. Methods: We characterized a cohort of nine patients with LOTS through a detailed clinical and video description. We then reviewed the available literature regarding the clinical description of patients with LOTS. Our findings were summarized based on the predominant phenotype of presentation to highlight diagnostic clues to guide the diagnosis of LOTS for different neurology specialists (neuromuscular, movement disorders) and psychiatrist. Results: We described a cohort of 9 new patients with LOTS seen at our clinic. Our literature review identified 76 patients mainly presenting with a neuromuscular, cerebellar, psychiatric, stuttering, or movement disorder phenotype. Diagnostic tips, such as the triceps sign, distinct speech patterns, early psychiatric presentation and impulsivity, as well as neurological symptoms (cerebellar or neuromuscular) in patients with a prominent psychiatric presentation, are described. Discussion: Specific diagnostics clues can help neurologists and psychiatrists in the early diagnosis of LOTS disease. Our work also represent the first video presentation of a cohort of patients with LOTS that can help different specialists to familiarize with these features and improve diagnostic outcomes. Highlights: Late-Onset Tay-Sachs (LOTS) disease, a severe progressive neurological condition, has multifaced presentations causing diagnostic delays that can significantly affect research outcomes now that clinical trials are available. We highlight useful diagnostic clues from our cohort (including the first video representation of a LOTS cohort) and comprehensive literature review.
Open Access Journal of Microbiology & Biotechnology · 2017 · 1 citations · open access
Study of Genetics Mutations in HEXA Gene for Induced Tay-Sachs Disease in Human, Tabriz, Iran
AbstractTay-Sachs disease is one of the few neurodegenerative diseases of known causes. It results from mutations of the HEXA gene encoding the alpha subunit of beta-hexosaminidase, producing a destructive ganglioside accumulation in lysosomes, principally in neurons. With the determination of the protein sequence of the alpha and beta subunits, deduced from cDNA sequences, the complex pathway of sub cellular and lysosomal processing of the enzyme has been determined.
Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy · 2023 · 0 citations · open access
Clinical and Molecular Findings of Nine Cases with Tay-Sachs Disease From Turkiye
AbstractObjective: Tay-Sachs disease is a fatal inherited lysosomal storage disease that mostly has an early infantile onset.We presented a case series of Tay-Sachs disease, describe the clinical and molecular findings, and compare the genetic spectrum with previously reported mutations from Türkiye. Methods: Patients with Tay-Sachs disease who were referred to the İstanbul University, İstanbul Faculty of Medicine, Department of Medical Genetics between January 2016 and December 2021 were included in this study.The diagnosis was confirmed by determining the level of serum β-hexosaminidase activity and the detection of a biallelic related variant upon Sanger sequencing of the HEXA gene.The clinical and molecular findings of nine cases were re-evaluated.Results: Three disease-causing variants in the HEXA gene including c.78G>A (p.(Trp26Ter)) in three cases, c.1177C>T (p.(Arg393Ter)) in two cases, and c.1100_1111del (p.(Gly367_Tyr370del)) in three cases were determined.Moreover, a novel c.786C>G (p.(His262Gln)) variant was detected in one case.All of the stated variants were identified in the homozygous state. Conclusion:Our study both reassessed and expanded the known mutation spectrum of Tay-Sachs disease in Türkiye.Given the expanding horizon of newborn screening and population carrier testing, understanding the spectrum of population-specific disease-causing variants will facilitate early diagnosis of patients and carriers.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
